Literature DB >> 11425419

Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.

J L Rocha, J Fernández-Alonso.   

Abstract

The nephrotoxic effect of COX-2 selective inhibitors has not yet been established. We report a case of reversible acute renal failure due to acute tubulointerstitial nephritis, confirmed by histology of a renal biopsy sample, associated with taking rofecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11425419     DOI： 10.1016/S0140-6736(00)05083-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  14 in total

1.  Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.

Authors:  Karlo Mihovilovic; Danica Ljubanovic; Mladen Knotek
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  [Selective cyclooxygenase-2 inhibitors for postoperative pain therapy. Analgesic efficacy and adverse effects].

Authors:  U Grundmann; J U Schreiber
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

Review 3.  Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Authors:  Ruth Savage
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.

Authors:  Jeffery T Fletcher; Nicole Graf; Anthony Scarman; Hamda Saleh; Stephen I Alexander
Journal:  Pediatr Nephrol       Date:  2006-09-06       Impact factor: 3.714

5.  Acute renal dysfunction associated with selective COX-2 inhibitor therapy.

Authors:  D Papaioannides; C Bouropoulos; D Sinapides; P Korantzopoulos; N Akritidis
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 6.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Renal failure associated with the use of celecoxib and rofecoxib.

Authors:  Syed R Ahmad; Cindy Kortepeter; Allen Brinker; Min Chen; Julie Beitz
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

Authors:  Neal M Davies; Xiao W Teng; Neil M Skjodt
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins.

Authors:  Jeramie D Watrous; Teemu J Niiranen; Kim A Lagerborg; Mir Henglin; Yong-Jiang Xu; Jian Rong; Sonia Sharma; Ramachandran S Vasan; Martin G Larson; Aaron Armando; Samia Mora; Oswald Quehenberger; Edward A Dennis; Susan Cheng; Mohit Jain
Journal:  Cell Chem Biol       Date:  2019-01-17       Impact factor: 8.116

Review 10.  Rofecoxib for rheumatoid arthritis.

Authors:  S E Garner; D D Fidan; R R Frankish; M G Judd; T E Towheed; G Wells; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.